GlassScriptPhysician profile
Thomas K Bond
NPI 1194752592
$671.37
in general payments reported to CMS, 2019-2025
16 companies · $14.80 in 2025
The $14.80 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.44 · 2020: $289 · 2021: $160 · 2022: $29.80 · 2023: $55.60 · 2024: $34.78 · 2025: $14.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $196.89 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.26 | 2020-2023 | Trintellix |
| Amgen INC. | $46.06 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $34.78 | 2024 | |
| Shire North American Group INC | $33.44 | 2019 | |
| Amarin Pharma, INC. | $32.69 | 2020-2021 | |
| Allergan, INC. | $20.61 | 2020 | |
| Redhill Biopharma INC. | $17.97 | 2020 | |
| Neos Therapeutics, LP | $17.16 | 2020 | |
| Lilly USA, LLC | $14.80 | 2025 | Zepbound |
| Avion Pharmaceuticals | $14.74 | 2021 | |
| Orthogenrx INC. | $14.54 | 2019 | |
| Vyera Pharmaceuticals, LLC | $14.04 | 2020 | |
| Daiichi Sankyo INC. | $13.37 | 2021 | |
| Acerus Pharmaceuticals Corporation | $11.78 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.